Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876066 | 0.94 | KCNH2 (0.39) | KCNH2HRH3MAPK1ALDH1A1USP2 | |
| SCHEMBL4865037 | 0.93 | KCNH2 (0.37) | KCNH2HRH3SCN9AMAPK1ALDH1A1 | |
| SCHEMBL4878273 | 0.91 | KCNH2 (0.34) | KCNH2HRH3GRM5PRCPMAPK1 | |
| SCHEMBL4874587 | 0.90 | MAPT (0.36) | KCNH2HRH3SCN9AMAPK1ALDH1A1 | |
| SCHEMBL4876396 | 0.88 | KCNH2 (0.36) | KCNH2HRH3MAPK1ALDH1A1USP2 | |
| SCHEMBL4877504 | 0.87 | KCNH2 (0.38) | KCNH2HRH3MAPK1ALDH1A1USP2 | |
| SCHEMBL4875611 | 0.87 | KCNH2 (0.45) | KCNH2HRH3MAPK1ALDH1A1 | |
| SCHEMBL4878064 | 0.86 | KDM4E (0.38) | KCNH2HRH3MAPK1ALDH1A1USP2 | |
| SCHEMBL4875364 | 0.86 | TP53 (0.34) | KCNH2HRH3ALDH1A1HPGD | |
| SCHEMBL4878862 | 0.86 | KCNH2 (0.36) | KCNH2HRH3MAPK1ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KCNH2 2647/4885HRH3 4258/4885GRM5 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.